Drug Discovery and the Market Today Part 2: Critical Thoughts on Stability
06/09/2010
David Elder
| stability
| stability testing
|
|
What are the 7 Deadly Sins of Quality Assurance and Quality Control?
Download our free QA QC eBook now to find out!
|
|
Dr. David Elder is the Externalization Director for GlaxoSmithKline. Here, he talks exclusively to Pharma IQ on his perspective across the industry, including CROs, regulations, and strategising for efficiency.
-
Drug Discovery and the Market Today Part 4: Developing Amorphous Forms -
Drug Discovery and the Market Today Part 5: Considering Genotoxic and Carcinogenic Impurities -
Drug Discovery and the Market Today: Video Exclusive with Dr. David Elder, GSK -
BHC- Product Supply: Pipeline Transparency & Risk Asssessment -
Recent Developments in Optimised Forecast Accuracy, Sales and Operations Planning at Merck Serono -
Drug Discovery and the Market Today Part 3: The Focus on Solubility -
Drug Discovery and the Market Today Part 1: An Overview of Externalisation in the Pharma Industry -
Implementing a Systematic and Transparent Approach to Post Approval Surveillance and Continued Safety Monitoring -
Vaccines and Pharmacovigilance: Meeting the Challenges in a Pandemic Situation -
Pharmacovigilance and Risk Management: Getting to Grips with the Evolving Regulatory Environment
You Should Check Out:
* = required.
Not a member yet? Sign up
Events of Interest
-
Stability Testing Training Online 2011
August 30, 2011
Register Now -
Global Formulation and Drug Delivery Summit 2012
Park Hotel Amsterdam, Netherlands
April 16- 18, 2012 -
Cold Chain Global Forum 2012
Chicago, IL
September 24- 28, 2012 -
Improving Solubility
Venue to be confirmed, Munich, Germany
June 26- 28, 2012
You Might Also Like
-
Getting to Grips with Stability Testing and Regulatory Compliance
What are the 7 Deadly Sins of Quality Assurance and Quality Control? Download our free QA QC... Read more
Helen Winsor
-
Establishing an Effective and Efficient Stability Testing Programme
Shekhar Natarajan, Senior Executive-CMC Regulatory Affairs, Johnson & Johnson discusses current
Pharma IQ
-
Formulation Strategy: Five Years From Now
What would you say are the main benefits of employing early formulation testing? Most small or virtual... Read more
David Elder








Not a member? Sign Up
Reasons for Joining
Address your challenges through knowledge sharing with peers from our global network of specialists.
Benchmark your business initiatives with the who's who in the field.
Hear from industry pioneers how to maximize ROI in today's challenging economy.
And best of all It's FREE!